NCT03306303|Completed
Loading search results
Sponsor study identifier
observational
1,700
0 countries
N/A
Study Start
January 1, 2014
Actual (reported)Primary Completion
October 1, 2017
Actual (reported)Study Completion
October 1, 2017
Actual (reported)ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 1, 2017
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2014
Actual (reported)October 1, 2017
Actual (reported)October 1, 2017
Actual (reported)October 2, 2017
Actual (reported)October 11, 2017
Actual (reported)a change in the prevalence of no-reflow
Thrombolysis in myocardial infarction (TIMI) flow grade of \<3 with a myocardial blush grade of 0-1 was defined as angiographic no-reflow
mediately after percutaneous coronary intervention (PCI)
in-hospital complications
up to 2 weeks after PCI
in-hospital major adverse cardiac or cerebrovascular events
up to 2 weeks after PCI
Quartile 1 of plasma melatonin
Quartile 2 of plasma melatonin
Quartile 3 of plasma melatonin
Quartile 4 of plasma melatonin
PLA general hospital (PLAGH) is a large national tertiary-care center in the Beijing, China. The investigators enrolled all patients consecutively hospitalized in PLAGH, with a diagnosis of STEMI and needed PCI.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, Reiter RJ. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res. 2012 Oct;53(3):319-23. doi: 10.1111/j.1600-079X.2012.01001.x. Epub 2012 Apr 27.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. The potential usefulness of serum melatonin level to predict heart failure in patients with hypertensive cardiomyopathy. Int J Cardiol. 2014 Jun 15;174(2):415-7. doi: 10.1016/j.ijcard.2014.04.044. Epub 2014 Apr 15. No abstract available.
melatonin, high-sensitivity C-reactive protein (hsCRP), superoxide dismutase levels
1,700 participants (actual enrollment reported by the registry).
First Submitted
October 2, 2017
First Posted
October 11, 2017
Study Start
January 1, 2014
Actual (reported)Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction
Contact the study team to confirm eligibility.
Tutuncu NB, Batur MK, Yildirir A, Tutuncu T, Deger A, Koray Z, Erbas B, Kabakci G, Aksoyek S, Erbas T. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res. 2005 Aug;39(1):43-9. doi: 10.1111/j.1600-079X.2005.00213.x.
Primary Completion
October 1, 2017
Actual (reported)Study Completion
October 1, 2017
Actual (reported)Last Updated
October 11, 2017
Record last verified: 2017-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: